ESH AL 2018 | Emerging novel approaches for ALL: inotuzumab ozogamicin
The prognosis for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) patients is poor, with low overall survival rates; however, novel therapies are showing promising results. Here, Wendy Stock, MD, of the University of Chicago Medical Centre, Chicago, IL, discusses the use of inotuzumab ozogamicin, a humanized anti-CD22 antibody-drug conjugate (ADC) in Phase III trials in both the R/R (NCT01564784) and frontline (NCT03150693) settings. Dr Stock also discusses the results of a trial testing this agent in the frontline setting in elderly patients, as well as a planned trial investigating a chemo-free ADC and BiTE approach. This video was recorded at the 2018 European School of Haematology (ESH) Clinical Updates on Acute Leukaemias, held in Budapest, Hungary.
Get great new content delivered to your inboxSign up